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Abstract: Rett syndrome (RTT) is an X-linked neurodevelopmental disorder affecting 1 in 10,000
live female births. Changes in microbiota composition, as observed in other neurological disorders
such as autism spectrum disorders, may account for several symptoms typically associated with
RTT. We studied the relationship between disease phenotypes and microbiome by analyzing diet,
gut microbiota, and short-chain fatty acid (SCFA) production. We enrolled eight RTT patients
and 10 age- and sex-matched healthy women, all without dietary restrictions. The microbiota
was characterized by 16S rRNA gene sequencing, and SCFAs concentration was determined by
gas chromatographic analysis. The RTT microbiota showed a lower α diversity, an enrichment
in Bacteroidaceae, Clostridium spp., and Sutterella spp., and a slight depletion in Ruminococcaceae.
Fecal SCFA concentrations were similar, but RTT samples showed slightly higher concentrations of
butyrate and propionate, and significant higher levels in branched-chain fatty acids. Daily caloric
intake was similar in the two groups, but macronutrient analysis showed a higher protein content in
RTT diets. Microbial function prediction suggested in RTT subjects an increased number of microbial
genes encoding for propionate and butyrate, and amino acid metabolism. A full understanding of
these critical features could offer new, specific strategies for managing RTT-associated symptoms,
such as dietary intervention or pre/probiotic supplementation.
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1. Introduction
Rett syndrome (RTT; OMIM 312750) is an X-linked neurodevelopmental disorder and one of the
most common causes of intellectual disability in females. 90%–95% percent of cases are associated
with mutations in the MECP2 (Methyl CpG Binding Protein 2) gene, encoding a chromatin-associated
protein that can both activate and repress transcription [1,2]. RTT is characterized by 6–18 months of
apparently normal neurodevelopment followed by neurological regression [3]. Neurological features
such as microcephaly, stereotyped hand movements, behavioral problems, seizures, and dyspraxia are
the main characteristics of RTT, but respiratory abnormalities and gastrointestinal dysfunctions are
also commonly reported [4]. RTT female patients, who are generally heterozygous for MECP2 gene
mutations, have variable MeCP2 expression (and varying phenotypes) due to random X-inactivation
patterns. Males who are null for MeCP2 expression are more severely affected and often do not
survive birth.
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Of the two MeCP2 protein isoforms generated by alternative splicing of the MECP2 gene
(MeCP2E1 and MeCP2E2), MeCP2E1 is the major isoform in the brain in both mice and humans,
and its deficiency is responsible for the phenotype [5].
Since MeCP2 is highly expressed in neurons, its loss and/or reduction might affect central nervous
system (CNS) development and function [6]. MeCP2 seems to act as a transcriptional modulator rather
than a classical transcriptional repressor [7], and MECP2 mutation type has been proposed as a strong
predictor of disease severity [8,9].
Recently, a MeCP2-dependent deregulation mechanism in the enteric nervous system (ENS)
has been demonstrated in a Mecp2-KO mouse model [10], highlighting ENS plasticity abnormalities
similar to CNS. Indeed, girls and women with RTT are characterized by an altered gastrointestinal
homeostasis and hypomotility that results in gastrointestinal discomfort, posing a significant burden
for their caregivers [11].
Recent results revealed the occurrence of an intestinal sub-inflammatory status in RTT and a
concomitant alteration of relative abundances of bacterial and fungal component in RTT subjects
compared with healthy controls [12]. Changes in microbiota composition, as observed in other
neurological disorders such as autism spectrum disorders (ASD) [13], may contribute to several typical
symptoms associated with RTT syndrome.
It has been shown that a dysbiotic gut microbiota may affect the function of the nervous system.
Putative mechanisms by which bacterial products affect central and enteric nervous systems are via
cytokine release from mucosal immune cells, via the release of gut hormones from enteroendocrine cells,
or via afferent neural pathways, including the vagus nerve [14]. This communication is bidirectional:
microbiota influences CNS function, and the CNS influences the microbiota composition through its
effects on the gastrointestinal tract [15].
Microbial short chain fatty acids (SCFAs), primarily acetate, butyrate, and propionate, are key
players in this landscape. Their production relies on various factors such as the microbial species
inhabiting the gut, the substrate source and availability, and the gut transit time [16].
Diet can have a marked impact on all the abovementioned factors [17,18], shaping the host
microbiota, providing a variety of fermentation substrates, and increasing or reducing fecal bulk and
its transit.
To date there has been no clear rationale for dietary intervention and/or pre-/probiotic
supplementation to improve gastrointestinal and neurophysiological symptoms in RTT patients.
Recently, RTT diet supplementation withω-3 polyunsaturated fatty acids was found to improve
the patient’s subclinical inflammatory status, partially restoring membrane fatty acids and correct
redox status [19].
At the same time, docosahexaenoic acid, a long-chain ω-3 polyunsaturated fatty acid, was shown
to promote changes in the gut microbial populations, and, in turn, some microbial genera such
as Bifidobacterium were demonstrated to improve the tissue distribution of docosahexaenoic acid,
especially in the brain [20].
Hence, the diet–microbiota–gut–brain pathway seems to represent a valid target of investigations
in order to mitigate or ameliorate disease progression.
In the present work, we characterized gut microbiota and fecal microbial metabolites in RTT
patients under unrestricted diet, as well as the correlation between these two players in RTT pathology.
2. Results
2.1. Cohort Description
We enrolled eight RTT female patients (mean age 23 ± 8.7 years) with different degrees of clinical
severity and identified the MECP2 gene mutation (Table 1).
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Table 1. Genetic defects and disease phenotypes of Rett syndrome (RTT) patients.
Patient MECP2 Mutation Type of Mutation Disease Phenotype SGS
R1 p. (R255 *) Nonsense Classic 12
R2 p. (L383Pfs) Frame-shift Classic 7
R3 c. (27 + 1_28 − 1)_(1461_?)del Intragenic deletion Classic 5
R4 p. (R133C) Missense Classic 5
R5 p. (R270Efs) Frame-shift Classic 10
R6 p. (R306C) Missense Classic 6
R7 p. (R294 *) Nonsense Classic 8
R8 p. (R106W) Missense Congenital 12
SGS: Severity Global Score. * Stop mutation is currently indicated by asterisk.
Their clinical phenotype was classified as classic (C; n = 7) or congenital (Co; n = 1). The mean
score of clinical severity using a modified severity score was 8 (range 5–12). Severity Global Score
(SGS) 4–6 was considered as mild phenotype, 7–9 as intermediate, and 10–12 as severe.
All but three subjects were able to walk independently; hand stereotypies were evident in all.
Six patients showed useful non-verbal communication, mainly through eye contact.
Epilepsy was diagnosed in seven subjects; three of them still had seizures, while four were
seizure-free. Seven patients were taking antiepileptic drugs: two patients were on monotherapy
(valproic acid and carbamazepine, respectively), whereas five were on polytherapy (three including
valproic acid, two including carbamazepine).
Gastrointestinal discomfort and constipation were present in all subjects, despite regular
feeding ability.
As a control group (controls, CTR), we included 10 mentally and physically healthy age-matched
women free of any medication (mean age 24.5 ± 6.6 years). The control group was not constipated.
All participants in the study did not take antibiotics or probiotics in the three months before the
enrollment, and were Caucasian, living in Northern Italy, and without any diet restriction.
Body mass index (BMI) was calculated using the formula: weight (kg)/height (m)2. BMI was
17.2 ± 3.9 (mean ± SD) in RTT patients, and 20.9 ± 2.2 in control group (p = 0.073).
2.2. Diet Evaluation
Since diet is one of the major environmental factors shaping gut communities, we analyzed the
dietary habits of the enrolled subjects. Dietary intake of energy, macronutrients, fiber, and cholesterol
is shown in Table 2, in comparison with “reference values” reported in the Nutrients and Energy
Reference Intake Levels for the Italian Population (LARN) [21].
Table 2. Daily macronutrient intake in RTT and control (CTR) individuals.
Variable RTTMean± SD
Control
Mean± SD p-Value Reference Values (LARN)
Energy
kcals 1739 ± 680 1493 ± 202 0.291 Women: 1790–2320 kcal (AR)
Proteins
g 70.3 ± 21.8 51.5 ± 12.2 0.033 * 43–50 g (AR)
g/kg weight 2.0 ± 0.6 1.0 ± 0.3 <0.001 *** 0.71 g/kg bw (AR)
% E 16 ± 4 14 ± 3 0.087 12%–15% E (RI)
Animal proteins
g 46.3 ± 19.8 31.3 ± 11.9 0.062
g/kg weight 1.3 ± 0.5 0.6 ± 0.3 <0.001 ***
Vegetal proteins
g 17.9 ± 6 20.2 ± 3.3 0.151
g/kg weight 0.5 ± 0.2 0.4 ± 0.1 0.180




Mean± SD p-Value Reference Values (LARN)
Total Carbohydrates
g 181.5 ± 65.9 209.0 ± 25.9 0.242
g/1000 kcal 107.0 ± 22.0 140.7 ± 13.9 0.001 **
% E 43 ± 9 56 ± 6 0.001 ** 45%–60% E (RI)
Sugars
% E 13 ± 3 15 ± 4 0.302 <15% E (SDT)
Fiber
g 11.3 ± 5.4 14.5 ± 5.3 0.225
g/1000 kcal 6.5 ± 1.6 9.9 ± 3.9 0.036 * 8.4–12.6 g/1000 Kcal
Fats
g 65.5 ± 15.0 52.9 ± 12.8 0.243
g/1000 kcal 37.3 ±7.8 35.2 ± 5.2 0.488
% E 33 ± 7 32 ± 5 0.488 20%–35% E (RI)
Saturated Fats
% E 8 ± 3 11 ± 4 0.117 <10% E (SDT)
Cholesterol
mg 244 ± 97 156 ± 66 0.035 * <300 mg·day
AR, average requirement; RI, reference intake; SDT, suggested dietary target; % E, percentage of total energy.
Significant differences are indicated by * p < 0.05, ** p < 0.01, and *** p < 0.001, Mann–Whitney test.
We did not observe differences (p = 0.291) in the mean value of daily energy intake between RTT
patients and controls; for both groups daily energy was lower than the average requirement (AR)
reported by (LARN) [21].
Compared with controls, RTT diets evidenced significantly higher level of proteins (p = 0.033),
exceeding the AR recommended. In particular, RTT diets were characterized by a higher content of
animal proteins (p = 0.062).
Carbohydrate intake (% of total energy) was significantly lower in RTT (p = 0.001), even though
about 75% of patients were within the recommended range.
Dietary fiber intake was also decreased in RTT patients (p = 0.036), and below the
recommended values.
2.3. Microbiota Dysbiosis in Rett syndrome (RTT) Patients Is Related to Disease Severity
The gut microbiota was characterized by next-generation sequencing using V3–V4 hyper-variable
16S rRNA genomic region.
On average, 90,390 ± 8648 high-quality reads were considered for gut microbiota analysis of RTT
(n = 8) and healthy controls (n = 10); reads were then grouped in a total of 3742 ± 1552 operational
taxonomic units (OTUs), which could be assigned to specific taxonomies down to the genus level.
The gut microbiota composition of the dataset (Figure S1) was dominated by bacteria belonging
to Firmicutes and Bacteroidetes (totaling about 90% of the total average relative abundance);
the subdominant phyla were Proteobacteria and Verrucomicrobia (4.8% and 3.1%, respectively).
This profile, even considering the alterations due to RTT, can be considered to be within the limits of a
typical Western-style microbiome. At the family level, the dominant groups were Bacteroidaceae,
Ruminococcaceae, and Lachnospiraceae (average relative abundance: 30.3%, 13.8%, and 13.0%,
respectively), followed by Rikenellaceae (8.7%), Veillonellaceae (7.8%), and Porphyromonadaceae (4.7%).
Sample R4, corresponding to one of our RTT patients, was characterized by a very low biodiversity,
as evident from the analysis of cumulative relative abundances at family level (Figure S2A,B), which
pointed out that in this sample 97% of the total relative abundance was due to only three families
(Bacteroidaceae, Ruminococcaceae, and Lachnospiraceae), whereas other samples (even in the RTT group)
reached about 90% at most. This is also reflected in the very low α-diversity values for this sample
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(Figure S2C,D). Moreover, the collected sample was characterized by liquid consistency (type 7 on
the Bristol Stool Scale [22]) and by a SCFA concentration below the detection limits, confirming that
it represents a clear outlier in our dataset. All other collected RTT samples were of solid consistency
(type 2/3 on Bristol Stool Scale). Thus, we decided to remove it from any further evaluation.
Bacterial composition within each sample (α-diversity) was measured using OTU-based methods
(Chao1, Figure S3A,B; observed species, Figure S3C,D; and Shannon indexes, Figure S3E,F),
and phylogenetic tree-based (PD-WT) method (Figure 1). First, we compared differences between RTT
patients and controls subjects (Figure 1A). Secondly, we examined the effect of disease severity on
bacterial communities (Figure 1B).
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Figure 1. α rarefaction curves according to Faith’s phylogenetic diversity index. (A) α-diversity plot of
Rett (red) versus control (blue) samples. RTT patients show a reduced biodiversity compared to healthy
controls. Differences are not statistically significant (p > 0.05); (B) Data grouped according to disease
severity. Severe stage (purple) samples show a reduced biodiversity compared to healthy controls
(blue), mild (orange), or intermediate (red) disease stage. Differences are not statistically significant
(p > 0.05).
Even though we could observe a reduction in α-diversity in RT patients, the number of subjects
analyzed was not sufficient to reach statistical significance (p > 0.05, permutation-based non-parametric
t-test) for all metrics. The obs rved reduction was more pronounced in atients with a severe form of
the disease.
To investigate differ nces in the two studied groups, we asse sed β-diversity using unweighted
(Figure 2) and weighted UniFrac distances (Figure S4).
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Figure 2. Principal Coordinate Analysis (PCoA) according to unweighted Unifrac distance. The first
two components of the variance are represented. (A) PCoA of Rett (red) versus control (blue) samples.
The two groups tend to separate according to PCoA 1 component. Differences are not statistically
significant (p > 0.05); (B) Samples are c lored according to disease sev rity. S vere s ge (purple)
significantly (p < 0.05) separates from healthy controls. Other differences are not statistically significant
(p > 0.05).
β-diversity analysis highlighted a certain separation (although not statistically significant)
between the centroids of RTT and CTR groups according to the unweighted Unifrac distance (p = 0.06).
Moreover, classification ccording to disease s verity highlighted how severe f rms of RTT result in a
completely different microbiota signature, as evidenced by the separation b tween severe stage RTT
patients and CTR (p = 0.02). These differences are likely due to subdominant components of the gut
microbiota, as also suggested by the fact that separation on weighted Unifrac metric is not significant
(Figure S4).
To evaluate possible differences in taxa distribution amongst RTT and control subjects,
we analyzed the relative microbial abundance at different taxonomic levels.
At the phylum level (Figure 3A), the predominant bacterial taxa in feces of both RTT and CTR
subjects were Bacteroidetes (CTR: 48.1 ± 19.2, RTT: 51.5 ± 11.2; mean ± sd) and Firmicutes (CTR:
41.9 ± 18.7, RTT: 35.9 ± 10.7), followed by Proteobacteria (CTR: 4.6 ± 4.3, RTT: 5.8 ± 5.0), Actinobacteria
(CTR: 3.0± 4.2, RTT: 3.6± 3.9), and Verrucomicrobia (CTR: 2.0± 2.6, RTT: 2. ± 3.4). The gut microbiota
of RTT patients was characteriz d by a slight increase in Bacteroidetes (+3.4% on average) and a decrease
in Firmicutes (−6.0% on average).
The most abundant families (Figure 3B) were Bacteroidaceae (CTR: 23.9± 5.6, RTT: 35.3± 7.4; mean± sd)
Ruminococcaceae (CTR: 17.8 ± 10, RTT: 11.5 ± 11.7), Lachnospiraceae (CTR: 14.9 ± 9.6, RTT: 10.8± 10.6),
Rikenellaceae (CTR: 9.5± 13.8, RTT: 8.6± 9.6), and Veillonellaceae (CTR: 7.2± 6.2, RTT: 10.9± 6.2).
RTT microbiota were enriched in Bacteroidaceae (as well as Bacteroides, p < 0.05),
Clostridium spp. (p < 0.01), Sutterella spp., and slightly depleted in Ruminococcaceae (as well as
Faecalibacte ium prasunitzii), Prevotella spp., and Roseburia spp.
We observed for some taxa a sev rity-related relative abund nce: Bacteroidaceae, Enterobacteriaceae,
and Erysipelotrichaceae increased, whereas Ruminococcaceae decreased from mild to severe disease
(Figure S5).
In order to determine whether body mass index could impact on intestinal microbiota ecology,
as observed in a previous study [23], we evaluated the relationship between BMI and microbiota
composition. BMI was positively correlated with Ruminococcaceae (p = 0.044), and inversely correlated
with Bacteroidaceae (as well as Bacteroides, p = 0.0174) and Veillonaceae abundance (p = 0.0472).
Correlation analysis between diet and microbiota showed that Bacteroides and Clostridium,
significantly increased in RTT, positively correlated with total protein and animal protein intake
(p < 0.05), whereas fiber intake was positively correlated with Christensenellaceae, and slightly increased
in the CTR group (Table S1).
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proteins and mino acid fermentation by proteolytic b cteria [16].
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Total SCFAs and acetate concentrations were positively correlated with the subject’s body mass
index (p = 0.029 and p = 0.021, respectively). A similar trend was observed for acetate (p = 0.021), which
was slightly increased in the CTR group compared with the RTT group. No correlation was seen for
butyrate and propionate.
We then evaluated possible associations between SCFA concentration and bacterial populations
(Figure 5).
Int. J. Mol. Sci. 2017, 18, 344  8 of 17 
 
Total SCFAs and acetate concentrations were positively co related with the subject’s body ass 
index (p = .     . , ti l ).  i il r t  as bserved for acetate (p = . 1), ich 
as slightly increased in the CTR group co pared ith the RTT group. o correlation as seen for 
butyrate and propionate. 
e then evaluated possible associations bet een S FA concentration and bacterial populations 
(Figure 5). 
 
Figure 5. Correlations between intestinal family- and genus-level phylogenetic groups and fecal 
short-chain fatty acids (SCFAs) (heatmap). Right panel: correlations between intestinal bacteria and 
SCFAs are indicated by colors (magenta: positive; blue: negative). Asterisks (*) indicate statistically 
significant correlations (p < 0.05); Left panel: mean relative abundances in RTT and CTR are reported. 
Significant differences are indicated by * p < 0.05, and ** p < 0.01, Mann–Whitney test. 
The Bacteroidaceae family showed an inverse and significant correlation (p < 0.05) with total 
SCFAs and acetate concentration, and seemed to slightly contribute to BCFA production. A similar 
trend was observed at the genus level for Bacteroides spp., whereas Parabacteroides, a saccharolytic 
genus belonging to Bacteroidetes, was positively correlated with propionate, butyrate, and BCFA 
concentrations (p < 0.05). Alcaligenaceae is positively correlated with propionate, whereas 
Porphyromonadaceae is positively correlated with propionate, butyrate, and BCFA concentration (all p 
< 0.05). 
All the abovementioned taxa were increased in RTT subjects and could be related to the different 
SCFAs concentrations observed. 
Moreover, RTT gut communities showed a reduction of Ruminococcaceae, and in particular of 
Faecalibacterium spp., the latter significantly correlating with total SCFAs and acetate production (p < 
0.05). 
Metabolic pathways are highly redundant in the gut microbiome [24], with several genera 
participating in carbohydrate and/or protein fermentation, and metabolite production. We applied 
PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) 
analysis to predict possible pathways enriched or depleted in RTT bacterial communities (Figure S6). 
At a broad functional level, the analysis predicted an enrichment in genes encoding enzymes for 
carbohydrate and lipid metabolism in the microbiota of healthy subjects, whereas the amino acids 
pathway was increased in RTT patients. However, genes for butanoate and propanoate metabolism 
were increased in the RTT microbial community (Figure 6). 
Figure 5. Correlations between intestinal family- and genus-level phylogenetic groups and fecal
short-chain fatty acids (SCFAs) (heatmap). Right panel: correlations between intestinal bacteria and
SCFAs are indicated by colors (magenta: positive; blue: negative). Asterisks (*) indicate statistically
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The Bacteroidaceae family showed an inverse and significant orrelation (p < 0.05) with total SCFAs
and acet te concentration, and seemed to slightly contribute to BCFA production. A similar trend was
observed at the genus level for Bacteroides spp., whereas Parabacteroides, a s ccharolytic genus belonging
to Bacteroidetes, was positively correlated with propionat , butyrate, and BCFA concentrations (p < 0.05).
Alcaligen ceae is positively correl ted with propi nate, whereas Porphyromonadaceae is positiv ly
cor elated with prop onate, but rate, and BCFA concentr tion (all p < 0.05).
All the abovementioned taxa were increased in RTT subjects and could be related to the different
SCFAs concentrations observed.
Moreov r, RTT gut communities showed a reduction of Ruminococcaceae, and in particular of
Faecalibact rium spp., the latter signif cantly corr lating with total SCFAs and a etat pro uction (p < 0.05).
Metabolic pathways r hi hly redundant in the gut microbiome [24], with several ge era
participating in carbohydrate and/or protein fermentation, and metabolite production. We applied
PICRUSt (Phylogenetic Investigation of Communi ies by Reconstruction of Unobserved Stat s) analysis
to predict poss ble pathways enriched or depleted in RTT bacterial communities (Figure S6). At broad
functional level, the analysis predicted an enrichment in genes encoding e zymes f r carbohydrate
and lipid metabolism in the microbiota of althy subjects, whereas the mino acids pathway was
increased in RTT patients. However, genes for bu ano te and propanoate m tabolism were incr ased
in the RTT microbial com unity (Figure 6).
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3. Discussion
Our stu y showed changes in the intestinal microbial profile t at could affect comorbidities
associated with RTT syndrome. This is the s cond study i vestigating the RTT icrobiome and the
first, to our knowledge, that compared dietary intakes, anthropometric measurements, microbial
profiles, and fecal SCFA concentrations.
Our data suggest that the RTT microbial population is reduced in richness and evenness.
Decreasing in α diversity directly correlated with disease phenotype: patients with higher scores of
clinical severity showed lower microbial diversity. Despite the small cohort enrolled, our results are in
agreement with what was observed by Strati and colleagues for the same syndrome [12], and with
other authors on subjects affected by ASD [25]. A rich microbial ecology promotes the fundamental
crosstalk and cross-feeding between species that guarantees the stability and resilience of the gut
ecosystem; loss of diversity is a consi tent trait of intestinal dysbiosis [26].
In our RTT cohort we found a slight reduction in Firmicutes and an increase in Bacteroidetes,
showing a pro-inflammatory status of the gut microbiota, in accordance with what was already
reported in studies on inflammatory bowel disease [27]. Interestingly, other neurological disorders,
such as Parkinson’s disease, also seem to be characterized by a similar gut microbiota profile [28].
Strati and colleagues observed an inverse trend in their RTT cohort. As previously described in
both children and adults [23,29], we found an inverse correlation between the relative abundance of
Bacteroidetes and body mass index (BMI). It is thus possible that the two studied cohorts were affected
by BMI variations justifying different trends.
On the other hand, our study confirm d an increase in RTT patients of Erysipelotrichace e, nd at
the genus level of Clostridium spp., Sutterella spp., and Escherichia spp. [12].
Erysipelotrichaceae have been suggested to be linked to gut inflammation, and to lipidemic
imbalance [30], features that have been reported in RTT syndrome [12,19], and our data indicate
a severity-related increase in abundance.
Bifidobacterium spp.’s relative abundance was similar in RTT and CTR subjects, irrespective to the
disease status, without confirming its overgrowth in RTT patients [12]. Our cohort was older than the
patients enrolled by Strati et al. (mean age 23 years compared with 12), and bifidobacteria abundance
is inversely correlated with age, and strongly dependent on diet [31–33]. An increase in bifidobacteria
has not been associated with any disease status, whereas a decrease has been observed in allergic
children, obese subjects, and the elderly [34].
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Diet is the major force shaping the gastrointestinal microbiota, and differences in macronutrient
intake can promote the overgrowth of selected microbial taxa [33]. Diet provides a variety of substrates
for bacterial fermentation, and consequently can alter microbial metabolite types and concentration.
Despite feeding difficulties, patients with RTT do not have any dietary restrictions [11]. In the RTT
group, we recorded higher protein consumption, mainly due to higher animal protein intake, and
a lower fiber intake in comparison with healthy controls, thus indicating different dietary patterns
between the two groups. Dietary intakes analysis showed that proteins, carbohydrates (% of total
energy), and dietary fiber intake were lower than those reported by LARN [21] in all the RTT subjects.
In the present study, reference values for healthy people were used as, to the best of our knowledge,
no dietary recommendations for RTT patients have been reported.
Further studies are needed to assess nutritional requirements in order to establish a dietetic
approach for these patients.
The above-described differences in microbiota communities did not result in differences in the
total fecal concentration of SCFAs, which was similar in all participants in our study, suggesting that
total colonic fermentation does not differ in the two groups. SCFA analysis was performed on wet
stool, thus not accounting for their water content. Although with this method SCFAs and BCFAs
might be highly concentrated, the literature supports this methodological approach, especially for RTT
patients, in view of their known constipation status [12].
In agreement with other studies, fecal total SCFA concentration was positively correlated with
BMI [23,29].
We found fecal butyrate and propionate to be increased in RTT patients, as well as iso-butyrate
and iso-valerate.
A functional group of bacteria, including Lachnospiraceae and Ruminococcaceae, has been identified
as responsible for butyrate intestinal concentration [35], but RTT microbiota was depleted in these
families. On the other hand, functional analysis with PICRUSt predicted in RTT patients an increase
in genes encoding enzymes involved in butanoate and propanoate metabolism. Recently, additional
enzymes involved in butyrate synthesis, alternatives to the acetyl-coenzyme A pathway, have been
recognized in many other bacterial taxa [36] and could account for the observed butyrate increase.
In particular, the lysine pathway indicates that protein, increased in the RTT diet, could also serve in
substrate butyrate synthesis [36].
Higher fecal butyrate concentrations could also result from its decreased absorption.
Butyrate adsorption, and thus inversely its fecal content, is dependent on gut transit time. A transit
>50 h promotes total butyrate oxidation by colonocytes that utilize it as a preferred energy source [37].
Constipation is common in RTT patients, prolonging bulk transit time; it is thus possible that the
increase in butyrate fecal content is linked to a reduction due to an altered colonocyte proliferation [38].
Butyrate plays a crucial role in gastrointestinal homeostasis by reducing inflammation, promoting
intestinal motility, and stimulating mucin production [39].
RTT subjects also show a slight increase in propionate fecal content, which is in line with a greater
abundance of Bacteroidetes and Veillonaceae, major propionate producers [40]. As observed by other
authors, propionate proportion showed a significant positive correlation with the Bacteroidetes [41].
Propionate is a substrate for hepatic gluconeogenesis and has been demonstrated to inhibit cholesterol
synthesis [16]. Besides the beneficial effects of propionate, its intraventricular direct infusion
into rat brains showed neurotoxicity potential, promoting the increase of oxidative stress and
neuroinflammation [42].
Protein fermentation is less studied than carbohydrates; however, it has been suggested that
branched-chain fatty acids (BCFAs) and other products coming from protein fermentation, such as
ammonia, phenols, amines, and sulfides, could affect the viability of colonocytes [43]. PICRUSt analysis
predicted higher amino acid metabolism in the RTT group, which is in line with the higher protein
intake. BCFAs derive from the degradation of protein, in particular from animal protein rich in
branched-chain amino acids, by proteolytic bacteria such as Bacteroidetes.
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We found RTT microbiota to share many alterations observed in ASD patients, such as enrichment
in Bacteroidaceae, Clostridium, and Sutterella [44,45], and reduction in Prevotella, and Coprococcus [25].
However, RTT patients showed a characteristic microbial signature that lacks the increase in
Desulfovibrionaceae and reduction in Veillonellaceae observed in ASD.
Until the last revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
published in 2013, RTT was included in Pervasive Developmental Disorders [46], because of the
absence of spoken language and the stereotyped behaviors. Autistic-like characteristics are mostly
evident in the regression phase, whereas in the later phases good eye contact distinguishes RTT patients
from ASD subjects. RTT syndrome is now considered a unique disease, with a well-defined genetic
background and clinical criteria [47].
Constipation is another common feature of RTT and ASD patients. However, the MECP2 defect
of RTT may itself account for gastrointestinal hypomotility [10]; we cannot rule out that this by itself is
responsible for shaping the diverse microbial colonization. It is also possible that genetic defects can
be ameliorated by SCFAs-derived compensatory effects. Acetate, and to a lesser extent butyrate and
propionate, can increase the colonic blood flow with effects on muscle contraction, tissue oxygenation,
and nutrient supply [37].
Drugs can also potentially alter the microbiota. The enrolled RTT patients were on different
antiepileptic therapies, but gut characteristics appear to be homogeneous between subjects. On the
other hand, we cannot rule out the specific influence of antiepileptic drugs (AEDs) on our results
because no data are available about AEDs’ impact on the gut microbiota. Vice versa, intestinal
microbiota can alter drug absorption [48], and there is evidence linking some commensal species to
the regulation of autoimmune responses triggering CNS inflammation [49].
Further studies are needed and encouraged in this field to identify possible relationships between
microbiota and AEDs in patients with epilepsy.
To date, effective therapies to cure RTT by restoring MECP2 gene function are lacking. At the
same time, caregivers are challenged by RTT-derived comorbidities such as constipation, epileptic
seizures, and growth retardation.
Unraveling the fine relationship between RTT dysbiosis and specific disease phenotype could offer
the chance to study alternative or combined therapies, patient-designed, to improve RTT-associated
symptoms and, ultimately, psycho-physical wellness.
Preliminary trials involving children with ASD showed that probiotic supplementation improves
antisocial behavior, anxiety, and communication problems. The resolution of gastrointestinal
discomfort itself resulted in an improvement of behavioral disturbances [50].
Beside probiotic supplementation, diet intervention, which is easily achievable, could offer a
further way to restore or improve microbial species that have been found to have decreased or increased
in RTT subjects.
Ketogenic diet interventions, assessed in mouse models of RTT and ASD, resulted in an
improvement in motor and social behavior [51]. Beneficial effects have also been obtained with
choline-rich [52] or anaplerotic triheptanoin diets [53].
A comprehensive study of a bigger cohort of RTT individuals, combining nutritional intervention
with detailed information on its effects on microbial community, microbial metabolites, biochemical
parameters, and neurophysiologic patterns could be fundamental to determining the most effective
treatment to ameliorate RTT patients’ quality of life.
4. Materials and Methods
4.1. Subject Recruitment
RTT subjects were enlisted from a cohort of patients referred to the Child Neuropsychiatry
Department of Santi Paolo Carlo Hospital (Milan, Italy). The diagnosis of RTT was made according
to the new Rett diagnostic criteria defined in 2010 [47]. Phenotypes of patients were categorized as
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follows: classic (C), congenital variant (Co), and preserved speech variant (PSV) [47]. Inclusion criteria
were clinical diagnosis of RTT and demonstrated MECP2 mutation, while exclusion criteria were the
use of antibiotics or probiotics in the three months before. As a control group, we included 10 mentally
and physically healthy girls who were not on any medication.
Evaluation of clinical severity included a detailed history and physical examination, and a
quantitative measures of global clinical status: a modified Severity Global Score (SGS) [54]. All scores
range from 1 to 3, with 1 representing the least severe and 3 representing the most severe cases.
From all subjects we collected stool samples, anthropometric data, and dietary habits.
Enrolled patients’ caregivers and control subjects filled in a food diary to calculate daily food intake in
kcal/day. Food diaries were processed by dieticians to calculate the average amounts of energy and
nutrient intake using commercially available software (MetaDieta®, Software version 3.1, METEDA
S.r.l., San Benedetto del Tronto, Italy). Anthropometric evaluation included measurements of height
and weight; body mass index was calculated and expressed as kg/m2.
The study protocol was approved by the Local Ethics Committee (protocol number 2016/ST/199,
28 July 2016); written informed consent was obtained from healthy subjects and from the parents or
legal guardians of the enrolled patients.
4.2. DNA Extraction and Preparation of 16s rRNA Gene Amplicon Libraries
Total bacterial DNA extraction was performed using the Spin stool DNA kit (Stratec Molecular,
Berlin, Germany), according to the manufacturer’s instructions and amplified by PCR. 25 ng of DNA
extracted from each stool sample was utilized to construct a sequencing library. 16S rRNA gene
amplicon libraries were performed with a two-step barcoding approach according to Illumina 16S
Metagenomic Sequencing Library Preparation (Illumina, San Diego, CA, USA). In the first-step PCR,
16S rRNA gene of all bacteria was amplified as described by Klindworth et al. [55]. Then, for library
preparation, DNA samples resulting from first PCR step were amplified with dual-index primers using
Nextera DNA Library Preparation Kit (Illumina). Each sample possessed specific barcode sequences at
the 5′- and 3′-end of the PCR amplicon to discriminate among each other in the pooled library. Library
concentration and exact product size were measured using a KAPA Library Quantification Kit (Kapa
Biosystems, Woburn, MA, USA) and an Agilent 2100 Bioanalyzer System (Agilent, Santa Clara, CA,
USA), respectively.
4.3. Sequencing via an Illumina MiSeq Platform
A pooled library (20 nM) and a PhiX control v3 (20 nM) (Illumina) were mixed with 0.2 N
fresh NaOH and hybridization buffer HT1 (Illumina) to produce the final concentration at 12 pM
each. The resulting library was mixed with the PhiX control v3 (5%, v/v) (Illumina) and 600 µL
loaded on a MiSeq® v2 (500 cycle) Reagent cartridge for obtaining a paired-end 2 × 250 bp
sequencing. All sequencing procedures were monitored through the Illumina BaseSpace® application.
Demultiplexed FASTQ files were generated by Illumina MiSeq Reporter and a total of 2.5 Gbases were
obtained (average of 286,167 reads per sample). Sequencing reads are available in NCBI Short Read
Archive (SRA, http://www.ncbi.nlm.nih.gov/sra) under ID PRJNA355083.
4.4. Short Chain Fatty Acid (SCFA) Measurement
SCFA concentrations were assessed in accordance with the method proposed by Weaver et al. [56],
modified as follows. Stool (200 mg) were suspended in 1 mL of double distilled water, homogenized
on a vortex mixer, and, after 30 min, centrifuged (15,000 rpm) for 15 min at 10 ◦C. Aliquots (0.5 mL)
of supernatant were added with 100 µL 85% orthophosphoric acid, 100 µL 2% (v/v), sulfuric acid and
100 µL of 2-ethyl-butyric acid (109959 Sigma-Aldrich, Milan, Italy) 10 mM in HCOOH 12% as internal
standard. SCFA were gently extracted for 1 min with 1 mL ethyl-ether/heptan (1:1 v/v) and centrifuged
for 10 min at 3000 rpm. The aqueous phase was frozen and the organic layer was removed for analysis
by a Varian 3400 CX (Conquer Scientific, San Diego, CA, USA) gas liquid chromatograph equipped
Int. J. Mol. Sci. 2017, 18, 344 13 of 17
with a Varian 8200 CX autosampler and an HP-FFAP fused-silica capillary column (30 m, 0.53 mm i.d.
with a 1-mm film). Injector and detector temperatures were 110 and 260 ◦C, respectively. The initial
oven temperature was 60 ◦C and was increased by 10 ◦C/min to 110 ◦C and then by 5◦ C/min and
held at 200 ◦C for 5 min. Quantification of the SCFA was obtained through calibration curves of acetic,
propionic, iso-butyric, butyric, and iso-valeric acid in concentrations between 2.5 and 10 mM (10 mM
2-ethyl-butyric acid as internal standard). Results are expressed as mg/g of wet weight of feces.
4.5. Data Analysis
Raw sequencing reads were processed merging together read pairs by using PandaSeq software
(Software version 2.5, “PAired-eND Assembler for DNA sequences”) [57], which performs a local
assembly between two overlapping pairs, generating a single fragment covering the whole V3–V4
amplicon. Fragments of length <250 bases or >900 bases, as well as non-overlapping sequences, were
discarded. Then, fragments were filtered using the “split_libraries_fastq.py” utility of the QIIME
suite [58], which filters out sequences having more than 25% nucleotides with a phred score of 3 or less.
Quality-filtered reads were then analyzed with the standard QIIME pipeline. Sequences were grouped
into OTUs (Operational Taxonomic Units) by using UCLUST [59] with 97% similarity threshold
and taxonomically classified against the 13.8 release of the Greengenes bacterial 16S rRNA database
(http://greengenes.lbl.gov) by RDP classifier [60] at 50% confidence. Singleton OTUs (i.e., clusters
made up of only 1 read) were discarded as possible artifacts or unlikely bona fide bacterial sequences.
Sample biodiversity (i.e., α diversity evaluation) was estimated according to different microbial
diversity metrics (i.e., chao1, Shannon index, observed species and Faith’s phylogenetic distance).
Inter-sample diversity (i.e., beta-diversity) was calculated using both weighted and unweighted
Unifrac metrics [61] and Principal Coordinates Analyses (PCoAs) were conducted. Data separation was
tested with a permutation test with pseudo F-ratios. For relative abundance analysis, a Mann–Whitney
U-test was used; a p-value <0.05 was chosen as the threshold for statistical significance. All statistical
evaluations were performed in Matlab (Software version 7.7.0, Natick, MA, USA).
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt)
1.0.0 [62] was applied to predict metagenome function from the 16S rRNA data.
We associated OTUs with known bacterial genomes precalculated in PICRUSt by picking
closed OTUs against the Greengenes 16S rRNA gene database (13.5). The resulting OTU table
was then normalized and used for metagenome inference of Kyoto Encyclopedia of Genes and
Genomes (KEGG) Orthologs using PICRUSt. Bray–Curtis distances were used to determine the
similarity of samples on the basis of metagenomic composition. Differences in the predicted
molecular functions of the bacterial communities of RTT and CTR groups were analyzed by the
linear discriminant analysis (LDA) effect size (LEfSe) [63] with default settings on the website
https://huttenhower.sph.harvard.edu/galaxy/root.
5. Conclusions
Gut microbiota produces an array of bioactive metabolic products that could exert profound
and dynamic effects on host metabolism and gene expression in many systems, including the Central
and the Enteric Nervous systems. A dysbiotic intestinal microbiota might contribute to or worsen
several RTT traits and might represent a possible disease marker and therapy target. Strategies aimed
at restoring normal gut microbiota, such as supplementation with pre/probiotics may represent a
non-pharmacological option not only for gastrointestinal disturbances, but also for behavioral and
neurophysiological abnormalities associated with RTT.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/2/344/s1.
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Abbreviations
AED Antiepileptic drug
ASD Autism spectrum disorders
BCFA Branched-chain fatty acids
BMI Body mass index
CNS Central nervous system
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ENS Enteric nervous system
LDA Linear discriminant analysis
MeCP2 Methyl CpG binding protein 2
OTU Operational taxonomic units
RTT Rett syndrome
SCFA Short-chain fatty acids
SGS Severity Global Score
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